Biopharmaceuticals: Approval trends in 2005

Gary Walsh

Biopharmaceuticals: Approval trends in 2005

Gary Walsh

Department of Chemical Sciences

Research output: Contribution to journal › Review article › peer-review

Abstract

Ten biopharmaceuticals gained marketing approval in the US and EU in 2005, although only five were genuinely new molecular entities.

Original language	English
Pages (from-to)	58-68
Number of pages	11
Journal	BioPharm International
Volume	19
Issue number	8
Publication status	Published - Aug 2006

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Cite this

@article{9cc5049f78214159812beb49baad0783,

title = "Biopharmaceuticals: Approval trends in 2005",

abstract = "Ten biopharmaceuticals gained marketing approval in the US and EU in 2005, although only five were genuinely new molecular entities.",

author = "Gary Walsh",

year = "2006",

month = aug,

language = "English",

volume = "19",

pages = "58--68",

journal = "BioPharm International",

issn = "1542-166X",

number = "8",

}

TY - JOUR

T1 - Biopharmaceuticals

T2 - Approval trends in 2005

AU - Walsh, Gary

PY - 2006/8

Y1 - 2006/8

N2 - Ten biopharmaceuticals gained marketing approval in the US and EU in 2005, although only five were genuinely new molecular entities.

AB - Ten biopharmaceuticals gained marketing approval in the US and EU in 2005, although only five were genuinely new molecular entities.

UR - https://www.scopus.com/pages/publications/33747164744

M3 - Review article

AN - SCOPUS:33747164744

SN - 1542-166X

VL - 19

SP - 58

EP - 68

JO - BioPharm International

JF - BioPharm International

IS - 8

ER -

Biopharmaceuticals: Approval trends in 2005

Abstract

UN SDGs

Other files and links

Fingerprint

Cite this